Additional Relevant Details New aesthetic indication in Japan for market-leading toxin demonstrates Allergan's long term commitment to innovation in medical aesthetics
Medical aesthetics is a fast growing healthcare sector in Japan, with a 56% rise in the number of surgical and non-surgical treatments performed from 2010 to 2014(1,2)

Japanese Ministry of Health, Labour and Welfare has approved an additional use for BOTOX Vista (Allergan's botulinum toxin type A product) as a treatment for crow's feet lines (CFL).3 BOTOX Vista is now indicated for the temporary improvement in the appearance of lateral canthal lines (CFL) in adult patients under the age of 65.